Bruce Turner Biography and Net Worth

Insider of Immunome

Bruce Turner is the founder of Talos Surgical, serving as Chairman since 2023, and the founder of Gennao Bio, Inc., serving as Director since 2020. Current jobs include President, CEO, Secretary, Treasurer & Director at Xanadu Bio Inc. since 2021 and Chief Strategy Officer at Immunome, Inc. since 2023. Former jobs include Managing Director at Boxer Capital LLC from 2017 to 2021, Principal at Hoffman-La Roche, Inc. from 2013 to 2017, and Chief Financial & Strategy Officer at MorphImmune, Inc. in 2023.

Education includes an undergraduate degree from The University of Chicago and a doctorate from the University of Pennsylvania Medical Center.

What is Bruce Turner's net worth?: The estimated net worth of Bruce Turner is at least $334,593.00 as of October 2nd, 2023. Turner owns 42,300 shares of Immunome stock worth more than $334,593 as of May 14th. This net worth estimate does not reflect any other assets that Turner may own. Learn More about Bruce Turner's net worth.
How do I contact Bruce Turner?: The corporate mailing address for Turner and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at investors@immunome.com. Learn More on Bruce Turner's contact information.
Has Bruce Turner been buying or selling shares of Immunome?: Bruce Turner has not been actively trading shares of Immunome over the course of the past ninety days. Most recently, on Monday, October 2nd, Bruce Turner bought 42,300 shares of Immunome stock. The stock was acquired at an average cost of $5.91 per share, with a total value of $249,993.00. Following the completion of the transaction, the insider now directly owns 42,300 shares of the company's stock, valued at $249,993. Learn More on Bruce Turner's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 418,262 shares worth more than $3,425,760.18. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 17,904 shares worth more than $279,313.12. The most recent insider tranaction occured on March, 26th when CEO Clay B Siegall bought 137,100 shares worth more than $999,459.00. Insiders at Immunome own 8.6% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/26/2025.

Bruce Turner Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/2/2023	Buy	42,300	$5.91	$249,993.00	42,300

Bruce Turner Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $7.91

$7.84

$8.37

50 Day Range

MA: $7.71

$5.56

$9.34

2 Week Range

Now: $7.91

$5.15

$16.81

Volume

1,771,365 shs

Average Volume

914,968 shs

Market Capitalization

$688.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Bruce Turner Biography and Net Worth

What is Bruce Turner's net worth?

How do I contact Bruce Turner?

Has Bruce Turner been buying or selling shares of Immunome?

Who are Immunome's active insiders?

Are insiders buying or selling shares of Immunome?